Form D
View Original Filing
Notice of Exempt Offering of Securities
Item 1. Issuer's Identity
Name of Issuer:
OLEMA PHARMACEUTICALS, INC.
Jurisdiction of Incorporation/Organization
DELAWARE
Year of Incorporation/Organization
Over Five Years Ago
Item 2 Issuer Principal Place of Business and Contact Information
665 3RD STREET SUITE 250
SAN FRANCISCO, CA 94107
Phone Number:
subscription required
Item 3. Related Persons
Name
CYRUS HARMON
Address
subscription required
Relationship(s)
- EXECUTIVE OFFICER
- DIRECTOR
Clarification of Response
Item 3. Related Persons
Name
PETER KUSHER
Address
subscription required
Relationship(s)
- EXECUTIVE OFFICER
- DIRECTOR
Clarification of Response
Item 3. Related Persons
Name
ANDREW RAPPAPORT
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
GORJAN HRUSTANOVIC
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
ANDREI MANOLIU
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
MARINA BOZILENKO
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
FRANK MCCORMICK
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
LAWRENCE FRITZ
Address
subscription required
Relationship(s)
Clarification of Response
Item 3. Related Persons
Name
DAVID MYLES
Address
subscription required
Relationship(s)
Clarification of Response
Item 4. Industry Group
PHARMACEUTICALS
Item 5. Issuer Size
Revenue Range (for issuer not specifying "hedge" or "other investment" fund in Item 4 above)
$5,000,001 - $25,000,000
Item 6. Federal Exemptions and Exclusions Claimed
Item 7. Type of Filing
New Notice
Date of First Sale in this Offering:
07/19/2018
Item 8. Duration of Offering
Does the issuer intend this offering to last more than one year?
No
Item 9. Type(s) of Securities Offered
- Equity
- Other: SERIES A-1 PREFERRED STOCK, SERIES A PREFERRED STOCK, AND COMMON STOCK ISSUABLE UPON CONVERSION THEREOF; COMMON STOCK ISSUED UPON CONVERSION OF PROMISSORY NOTES.
Item 10. Business Combination Transaction
Is this offering being made in connection with a business combination
transaction, such as a merger, acquisition or exchange offer?
No
Clarification of Response
Item 11. Minimum Investment
Minimum Investment accepted from any outside investor
0
Item 13. Offering and Sales Amounts
Total Offering Amount
6054922
Total Amount Sold
6054922
Total Remaining to be Sold
0
Clarification of Response
Item 14. Investors
Securities in the offering have been or may be sold to persons
who do not qualify as accredited investors,
Number of non-accredited investors who already have invested in the offering:
Total number of investors who already have invested in the offering:
13
Item 15. Sales Commissions and Finders' Fees Expenses
Sales Commissions:
0.0
Finders' Fees
0.0
Clarification of Response
Item 16. Use of Proceeds
Provide the amount of the gross proceeds of the offering
that has been or is proposed to be used for payments to any of the persons required
to be named as executive officers,directors or promoters in response to Item 3 above.
0.0
Clarification of Response
Signature and Submission
Issuer Name
OLEMA PHARMACEUTICALS, INC.
Issuer Signature
/S/ CYRUS L. HARMAN
Signer Name
CYRUS L. HARMAN
Signer Title
CEO
Signature Date
08/23/2018